Oncotelic Therapeutics, Inc.
OTLC
$0.03
$0.001.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 250.00K | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 250.00K | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 250.00K | -- | -- | -- | -- |
| SG&A Expenses | 5.76M | 4.73M | 2.98M | 689.70K | 279.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.77M | 4.74M | 2.99M | 689.60K | 279.40K |
| Operating Income | -5.52M | -4.74M | -2.99M | -689.60K | -279.40K |
| Income Before Tax | 358.83M | 358.70M | 360.57M | -1.92M | -4.18M |
| Income Tax Expenses | 111.55M | 111.55M | 111.55M | -- | -- |
| Earnings from Continuing Operations | 247.28 | 247.15 | 249.02 | -1.92 | -4.18 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 214.60K | 234.90K | 254.90K | 253.40K | 253.60K |
| Net Income | 247.50M | 247.38M | 249.28M | -1.67M | -3.93M |
| EBIT | -5.52M | -4.74M | -2.99M | -689.60K | -279.40K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.56 | 0.56 | 0.56 | 0.00 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.56 | 0.56 | 0.56 | 0.00 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 1.76B | 1.72B | 1.68B | 1.65B | 1.63B |
| Average Diluted Shares Outstanding | 1.78B | 1.76B | 1.73B | 1.69B | 1.67B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |